ViaCyte is a regenerative medicine company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for all type 1 diabetes and a next-generation treatment for insulin-requiring type 2 diabetes.
What company is working on a cure for diabetes?
Vertex Pharmaceuticals announced this week that it is buying Semma Therapeutics for $950 million in cash. Massachusetts-based Semma specializes in stem cell therapies, and has aroused some hype over its current efforts to cure type 1 diabetes.
When will ViaCyte be available?
Patients in the trial will be implanted with the device for one year. The company expects to make preliminary data from the trial publicly available in the second half of 2021; the trial is projected to be completed in April 2023.
How does ViaCyte work?
We’ve been watching ViaCyte for years, as the San Diego company works towards a method of “reprogramming” human stem cells to grow into new insulin-producing cells that would be implanted in the body housed in a tiny device — effectively, a functional cure.
Does ViaCyte use embryonic stem cells?
ViaCyte does not deliver stem cells as a product. ViaCyte uses pluripotent stem cells as a starting material to make its cell products.
Can diabetes be cured completely?
There is no known cure for type 2 diabetes. But it can be controlled. And in some cases, it goes into remission. For some people, a diabetes-healthy lifestyle is enough to control their blood sugar levels.
Can diabetes be reversed naturally?
Although there’s no cure for type 2 diabetes, studies show it’s possible for some people to reverse it. Through diet changes and weight loss, you may be able to reach and hold normal blood sugar levels without medication. This doesn’t mean you’re completely cured. Type 2 diabetes is an ongoing disease.
What does sernova Corp do?
ABOUT SERNOVA Sernova Corp is developing regenerative medicine therapeutic solutions using a medical device (Cell Pouch™) and immune protected therapeutic cells/tissues (i.e., human donor cells, corrected human cells and stem cell- derived cells) to improve the treatment and quality of life of people with chronic …
Is ViaCyte publicly traded?
ViaCyte is a privately-funded regenerative medicine company focused on cell replacement therapies for unmet medical needs. Our investors are major supporters and experienced partners in the life science sectors.
What is VC 02?
Patients who receive PEC-Direct must take immunosuppressants to protect the cells, making it suitable only for people with high-risk type 1 diabetes. The PEC-Direct product candidate is being developed for type 1 diabetes patients who have hypoglycemia unawareness and/or extreme glycemic lability.
How does ViaCyte protect the therapeutic cells from the patient’s immune system?
ViaCyte has multiple therapeutic approaches to propel clinical development. For PEC-Encap, PEC-01 cells are loaded into the Encaptra system, which is implanted under the patient’s skin (subcutaneously). The Encaptra system is designed to encapsulate and protect the cells from the immune system.
What are pluripotent stem cells?
Pluripotent stem cells are cells that have the capacity to self-renew by dividing and to develop into the three primary germ cell layers of the early embryo and therefore into all cells of the adult body, but not extra-embryonic tissues such as the placenta.